Nuvectis Pharma (NASDAQ:NVCT) reported quarterly earnings results on February 11, 2026 that fell short of analyst expectations.
The Healthcare company reported earnings per share of $-0.31, missing the consensus estimate of $-0.28 by $0.03 per share. Revenue came in at , meeting the estimate of .
Nuvectis Pharma's stock moved following the earnings release. The stock currently trades at $8.69 with a market capitalization of $192.8M.